1. US Diabetes Drugs Market - Prevalence and Statistics

2. US Diabetes Drugs Market Overview

  2.1 Current Market Scenario

  2.2 Clinical Trials Landscape

3. US Insulins Based Drugs - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  3.1 Insulin Lispro

  3.2 Insulin Glargine

  3.3 Insulin Aspart

  3.4 Insulin Detemir

  3.5 Insulin Regular

  3.6 Insulin Aspart / Insulin Aspart Protamine

  3.7 Insulin Degludec

  3.8 Insulin Glulisine

  3.9 Insulin Inhalation

  3.10 Insulin Isophane / Insulin Regular

  3.11 Insulin Isophane

  3.12 Insulin Lispro / Insulin Lispro Protamine

4. Non-Sulfonylureas - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  4.1 Metformin

5. Sulfonylureas - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  5.1 Chlorpropamide

  5.2 Glimepiride

  5.3 Glyburide

  5.4 Glipizide

  5.5 Tolazamide

  5.6 Tolbutamide

6. Thiazolidinediones - Branded and Generic Availability, Dosage, Patent and Price

  Analysis

  6.1 Pioglitazone

  6.2 Rosiglitazone

7. Incretin mimetics - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  7.1 Liraglutide

  7.2 Exenatide

  7.3 Semaglutide

  7.4 Dulaglutide

  7.5 Lixisenatide

8. Dipeptidyl peptidase 4 inhibitors - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  8.1 Sitagliptin

  8.2 Saxagliptin

  8.3 Linagliptin

  8.4 Alogliptin

9. SGLT-2 inhibitors - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  9.1 Canagliflozin

  9.2 Ertugliflozin

  9.3 Empagliflozin

  9.4 Dapagliflozin

10. Meglitinides - Branded and Generic Availability, Dosage, Patent and Price Analysis

  10.1 Repaglinide

  10.2 Nateglinide

11. Alpha-glucosidase inhibitors - Branded and Generic Availability, Dosage, Patent and Price Analysis

  11.1 Miglitol

  11.2 Acarbose

12. Combinational - Branded and Generic Availability, Dosage, Patent, Price and Sales Analysis

  12.1 Metformin/Sitagliptin

  12.2 Glimepiride/Pioglitazone

  12.3 Glyburide/Metformin

  12.4 Dapagliflozin/Metformin

  12.5 Empagliflozin/Metformin

  12.6 Glipizide/Metformin

  12.7 Linagliptin/Metformin

  12.8 Metformin/Pioglitazone

  12.9 Metformin / Saxagliptin (Kombiglyze XR)

  12.10 Alogliptin / Metformin (Kazano)

  12.11 Alogliptin / Pioglitazone (Oseni)

  12.12 Canagliflozin/Metformin (Invokamet/ Invokamet XR)

  12.13 Dapagliflozin / Saxagliptin (Qtern)

  12.14 Empagliflozin / Linagliptin / Metformin

  12.15 Empagliflozin / Linagliptin (Glyxambi)

  12.16 Ertugliflozin / Metformin (Segluromet)

  12.17 Ertugliflozin / Sitagliptin (Steglujan)

13. Other Antidiabetic Drugs - Branded and Generic Availability, Dosage, Patent and Price Analysis

  13.1 Bromocriptine (Cycloset)

  13.2 Colesevelam (Welchol)

  13.3 Pramlintide (Symlin)

14. Compititive Landscape

  14.1 AstraZeneca

  14.2 Boehringer Ingelheim

  14.3 Daiichi Sankyo

  14.4 Eli Lilly

  14.5 GSK

  14.6 Janssen Pharma

  14.7 Merck

  14.8 Novartis

  14.9 Novo Nordisk

  14.10 Pfizer

  14.11 Sanofi

  14.12 Takeda

Figure 1-1:  US – Estimated Diabetic Population (Million), 2019, 2025, 2030 and 2045

Figure 1-2:  US – Undiagnosed and Diagnosed Diabetic Population (Million), 2019

Figure 1-3:  US – Undiagnosed and Diagnosed Diabetic Population (%), 2019

Figure 1-4:  US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 and 2045

Figure 1-5:  US – Diabetic Population by Type (Million), 2019

Figure 1-6:  US – Diabetic Population by Type (%), 2019

Figure 1-7:  US – Type 1 Diabetes Cases by Age (Million), 2019

Figure 1-8:  US – Maximum Diabetic Prevalence Rate by States (%), 2020

Figure 1-9:  US – Minimum Diabetic Prevalence Rate by States (%), 2020

Figure 2-1: US – Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026

Figure 2-2: Global – Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026

Figure 2-3: North America – Diabetes Drug Market Size US v/s Others (US$ Billion), 2020

Figure 2-4: US – Insulin Market Opportunity (US$ Billion), 2019 - 2026

Figure 2-5: US – Diabetes Drug Market by Product (US Billion), 2020

Figure 2-6: US – Diabetes Drug Market by Product (%), 2020

Figure 2-7: US - Number of  Diabetes Drug Clinical Pipeline by Phase, 2021 - 2026

Figure 2-8: US - Number of Diabetes Drugs in Clinical Pipeline by Drug Class, 2021 - 2026

Figure 2-9: US - Number of Diabetes Drugs in Clinical Pipeline by Organization, 2021 - 2026

Figure 2-10: US - Number of Diabetes  Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026

Figure 3-1: US – Insulin Lispro FDA Approval and Patent Expiration Year

Figure 3-2: US – FDA Approval History by Brand Name

Figure 3-3: Humalog – Cost of Supply of 3ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-4: Humalog – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-5: Humalog KwikPen – Cost of 15ml and Per Unit Cost of Injectable Solution (US$), February’2021

Figure 3-6: Humalog KwikPen – Cost of 6ml and Per Unit Cost of Subcutaneous Solution (US$), February’2021

Figure 3-7: Admelog – Cost of Supply of 3ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-8: Admelog – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-9: Lyumjev - Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-10: Humalog Junior KwikPen - Cost of Supply of 15ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-11: Insulin Lipro - Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-12: Insulin Lispro – Price Per ml By Brand Name (US$)

Figure 3-13: Global – Humalog Annual Sales (US$ Million), 2017-2020

Figure 3-14: Global – Admelog Annual Sales (US$ Million), 2018 and 2019

Figure 3-15: US - Admelog Annual Sales (US$ Million), 2018 and 2019

Figure 3-16: Admelog – Annual Sales by Region (US$ Million), 2019

Figure 3-17: Admelog – Annual Sales by Region (%), 2019

Figure 3-18: Global – Admelog Quarterly Sales (US$ Million), 2019

Figure 3-19: US – Admelog Quarterly Sales (US$ Million), 2019

Figure 3-20: Global – Admelog Quarterly Sales (US$ Million), 2020

Figure 3-21: US – Insulin Glagrine FDA Approval and Patent Expiration Year

Figure 3-22: Insulin Glagrine – FDA Approval History by Brand

Figure 3-23: Lantus – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-24: Basaglar – Cost of Supply of 15ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-25: Toujeo - Cost of Supply of 4.5ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-26: Lantus Solostar- Cost of Supply of 15ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-27: Semglee - ost of Supply of 10ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-28: Global – Lantus Annual Sales (US$ Million), 2017-2019

Figure 3-29: US - Lantus Annual Sales (US$ Million), 2017- 2019

Figure 3-30: Lantus – Annual Sales by Region (US$ Million), 2019

Figure 3-31: Lantus – Annual Sales by Region (%), 2019

Figure 3-32: Global – Lantus Quarterly Sales (US$ Million), 2019

Figure 3-33: US –Lantus Quarterly Sales (US$ Million), 2019

Figure 3-34: Global – Lantus Quarterly Sales (US$ Million), 2020

Figure 3-35: US - Lantus Quarterly Sales (US$ Million), 2020

Figure 3-36: Lantus – Annual Sales by Region (%), 2020

Figure 3-37: Global –Basaglar Annual Sales (US$ Million), 2017-2020

Figure 3-38: Global – Toujeo Annual Sales (US$ Million), 2017-2019

Figure 3-39: US - Toujeo Annual Sales (US$ Million), 2017- 2019

Figure 3-40: Toujeo – Annual Sales by Region (US$ Million), 2019

Figure 3-41: Toujeo – Annual Sales by Region (%), 2019

Figure 3-42: Global – Toujeo Quarterly Sales (US$ Million), 2019

Figure 3-43: US – Toujeo Quarterly Sales (US$ Million), 2019

Figure 3-44: Global – Toujeo Quarterly Sales (US$ Million), 2020

Figure 3-45: US - Toujeo Quarterly Sales (US$ Million), 2020

Figure 3-46: Toujeo – Annual Sales by Region (%), 2020

Figure 3-47: US – Insulin Aspart FDA Approval and Patent Expiration Year

Figure 3-48: US – FDA Approval History by Brand

Figure 3-49: Novolog – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), Fbruary’2021

Figure 3-50: Novolog PenFill – Cost of Supply of 15ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-51: Fiasp – Cost of Supply of 15ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-52: Fiasp – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-53: Insulin Aspart – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-54: Global – Fiasp Annual Sales (US$ Million), 2018-2020

Figure 3-55: US - Fiasp Annual Sales (US$ Million), 2018-2020

Figure 3-56: Fiasp – Annual Sales by Region (%), 2019

Figure 3-57: Fiasp – Annual Sales by Region (%), 2020

Figure 3-58: US – Insulin Detemir FDA Approval and Patent Expiration Year

Figure 3-59: Levemir – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-60: Global – Levemir Annual Sales (US$ Million), 2018-2020

Figure 3-61: US - Levemir Annual Sales (US$ Million), 2018-2020

Figure 3-62: Levemir – Annual Sales by Region (%), 2019

Figure 3-63: Levemir – Annual Sales by Region (%), 2020

Figure 3-64: US – Insulin Regular FDA Approval and Patent Expiration Year

Figure 3-65: Insulin Regular – FDA Approval Year by Brand

Figure 3-66: Humulin – Cost of Supply of 3ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-67: Humulin – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-68: Novolin – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-69: Humulin R U-500 – Cost of Supply of 20ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-70: Humulin KwikPen– Cost of Supply of 6ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-71: Myxredlin– Cost of Supply of 1200ml and Per Unit Price of Intravenous Solution (US$), February’2021

Figure 3-72: Global – Humulin Annual Sales (US$ Million), 2017-2020

Figure 3-73: Novolog Mix 70/30 - Cost of Supply of 10ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-74: Novolog Mix 70/30 FlexPen - Cost of Supply of 15ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-75: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 15ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-76: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 10ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-77: Global – NovoMix Annual Sales (US$ Million), 2018-2020

Figure 3-78: US - NovoMix Annual Sales (US$ Million), 2018-2020

Figure 3-79: NovoMix – Annual Sales by Region (%), 2019

Figure 3-80: NovoMix – Annual Sales by Region (%), 2020

Figure 3-81: US – Insulin Degludec FDA Approval and Patent Expiration Year

Figure 3-82: Tresiba- Cost of Supply of 10ml and Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021

Figure 3-83: Tresiba- Cost of Supply of 15ml and Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021

Figure 3-84: Tresiba- Cost of Supply of 9ml and Per Unit Price of 200units/ml Subcutaneous Solution (US$), February’2021

Figure 3-85: Global – Tresiba Annual Sales (US$ Million), 2018-2020

Figure 3-86: US - Tresiba Annual Sales (US$ Million), 2018-2020

Figure 3-87: Tresiba – Annual Sales by Region (%), 2019

Figure 3-88: Tresiba – Annual Sales by Region (%), 2020

Figure 3-89: US – Insulin Glusine FDA Approval and Patent Expiration Year

Figure 3-90: US – FDA Approval Year by Brand

Figure 3-91: Apidra – Cost of Supply of 10ml and Per Unit Price of injectable solution (US$), February’2021

Figure 3-92: Global – Apidra Annual Sales (US$ Million), 2017-2019

Figure 3-93: US - Apidra Annual Sales (US$ Million), 2017- 2019

Figure 3-94: Apidra – Annual Sales by Region (US$ Million), 2019

Figure 3-95: Apidra – Annual Sales by Region (%), 2019

Figure 3-96: Global – Apidra Quarterly Sales (US$ Million), 2019

Figure 3-97: US – Apidra Quarterly Sales (US$ Million), 2019

Figure 3-98: Global – Apidra Quarterly Sales (US$ Million), 2020

Figure 3-99: US - Apidra Quarterly Sales (US$ Million), 2020

Figure 3-100: Apidra – Annual Sales by Region (%), 2020

Figure 3-101: Afrezza – Cost of Supply of 90 Powders and Per Unit Cost of 4 Units Powder (US$), February’2021

Figure 3-102: Afrezza – Cost of Supply of 90 Powders and Per Unit Cost of 8 Units Powder (US$), February’2021

Figure 3-103: Afrezza – Cost of Supply of 90 Powders and Per Unit Cost of 12 Units Powder (US$), February’2021

Figure 3-104: Insulin Isophane/Insulin Regular – FDA Approval Year by Brand

Figure 3-105: Humulin 70/30 – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-106: Humulin 70/30 – Cost of Supply of 3ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-107: Humulin 70/30 Pen – Cost of Supply of 15ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-108: Novolin 70/30 – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-109: ReliON – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-110: Insulin Isophane – FDA Approval Year by Brand

Figure 3-111: Humulin N – Cost of Supply of 3ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-112: Humulin N – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-113: Humulin N Pen – Cost of Supply of 15ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-114: Novolin N – Cost of Supply of 10ml and Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-115: Humalog Mix 50/50 – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-116: Humalog Mix 50/50 Pen – Cost of Supply of 15ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-117: Humalog Mix 75/25 – Cost of Supply of 10ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 3-118: Humalog Mix 50/50 Pen – Cost of Supply of 15ml and Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 4-1: Metformin – FDA Approval and 1st Generic Approval Year

Figure 4-2: Metformin – FDA Approval Year by Brand

Figure 4-3: US – Glumetza Patent Approval and Expiration Year

Figure 4-4: US – Riomet Patent Approval and Expiration Year

Figure 4-5: Glumetza – Cost of Supply of 100 Tablets and Per Unit Price of 500mg Oral Tablet (US$), February’2021

Figure 4-6: Glumetza – Cost of Supply of 90 Tablets and Per Unit Price of 1000mg Oral Tablet (US$), February’2021

Figure 4-7: Glumetza – Per Unit Cost of 500mg and 100mg Oral Tablet (US$), February’2021

Figure 4-8: Glumetza – Maximum and Minimum Recommended Dose (mg)

Figure 4-9: Riomet – Cost of Supply of 118ml and Per Unit Price of Oral Soltuion (US$), February’2021

Figure 4-10: Riomet – Cost of Supply of 473ml and Per Unit Price of Oral Soltuion (US$), February’2021

Figure 4-11: Riomet – Maximum and Minimum Recommended Dose (mg)

Figure 4-12: Riomet – Cost of Supply of 118ml and 473ml of Oral Soltuion (US$), February’2021

Figure 4-13: Metformin – Cost of Supply of 30, 90 and 100 Oral Tablets (500mg) (US$), February’2021

Figure 4-14: Metformin – Cost of Supply of 30, 90 and 100 Oral Tablets (850mg) (US$), February’2021

Figure 4-15: Metformin – Cost of Supply of 30, 90 and 100 Oral Tablets (1000mg) (US$), February’2021

Figure 4-16: Metformin – Cost of Supply of 30, 90 and 100 Oral ER Tablets (750mg) (US$), February’2021

Figure 5-1: Chlorpropamide – Cost of Supply of 30 and 60 Oral Tablets (250mg) (US$), February’2021

Figure 5-2: Chlorpropamide – Cost of Supply of 30 and Per Unit Price of Oral Tablets (100mg) (US$), February’2021

Figure 5-3: Chlorpropamide – Maximum and Minimum Recommended Dose (mg)

Figure 5-4: Glimepiride – FDA Approval and 1st Generic Approval Year

Figure 5-5: US – Glimepiride Patent Approval and Expiration Year

Figure 5-6: Amaryl – Cost of Supply of 100 Tablets and Per Unit Price of 1mg Oral Tablet (US$), February’2021

Figure 5-7: Amaryl – Cost of Supply of 100 Tablets and Per Unit Price of 2mg Oral Tablet (US$), February’2021

Figure 5-8: Amaryl – Cost of Supply of 100 Tablets and Per Unit Price of 4mg Oral Tablet (US$), February’2021

Figure 5-9: Glimepiride – Cost of Supply of 30, 90 and 100 Oral Tablets (1mg) (US$), February’2021

Figure 5-10: Glimepiride – Cost of Supply of 30, 90 and 100 Oral Tablets (2mg) (US$), February’2021

Figure 5-11: Glimepiride – Cost of Supply of 30, 90 and 100 Oral Tablets (4mg) (US$), February’2021

Figure 5-12: Glimepiride – Maximum and Minimum Recommended Dose (mg)

Figure 5-13: Glyburide – FDA Approval and 1st Generic Approval Year

Figure 5-14: DiaBeta – Cost of Supply of 50 Tablets and Per Unit Price of 1.25mg Oral Tablet (US$), February’2021

Figure 5-15: DiaBeta – Cost of Supply of 100 Tablets and Per Unit Price of 2.25mg Oral Tablet (US$), February’2021

Figure 5-16: DiaBeta – Cost of Supply of 100 Tablets and Per Unit Price of 5mg Oral Tablet (US$), February’2021

Figure 5-17: Glynase PresTab – Cost of Supply of 100 Tablets and Per Unit Price of 1.5mg Oral Tablet (US$), February’2021

Figure 5-18: Glynase PresTab – Cost of Supply of 100 and 1000 Tablets of 3mg Oral Tablet (US$), February’2021

Figure 5-19: Glynase PresTab – Cost of Supply of 100 and 500 Tablets of 6mg Oral Tablet (US$), February’2021

Figure 5-20: Glyburide– Cost of Supply of 50 and 100 Tablets of 1.5mg Oral Tablet (US$), February’2021

Figure 5-21: Glyburide– Cost of Supply of 30, 90 and 100 Tablets of 2.5mg Oral Tablet (US$), February’2021

Figure 5-22: Glyburide– Cost of Supply of 30, 90 and 100 Tablets of 5mg Oral Tablet (US$), February’2021

Figure 5-23: Glyburide – Cost of Supply of 100 Tablets and Per Unit Price of 1.5mg Micronized Oral Tablet (US$), February’2021

Figure 5-24: Glyburide – Cost of Supply of 100 and 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021

Figure 5-25: Glyburide – Cost of Supply of 100 and 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021

Figure 5-26: Glyburide – Maximum and Minimum Recommended Dose of Standard Tablet (mg)

Figure 5-27: Glyburide – Maximum and Minimum Recommended Dose of Micronized Tablet (mg)

Figure 5-28: Glipizide – FDA Approval and 1st Generic Approval Year

Figure 5-29: Glucotrol – Cost of Supply of 100 Tablets and Per Unit Price of 5mg Oral Tablet (US$), February’2021

Figure 5-30: Glucotrol – Cost of Supply of 100 Tablets and Per Unit Price of 10mg Oral Tablet (US$), February’2021

Figure 5-31: Glucotrol XL – Cost of Supply of 30 Tablets and Per Unit Price of 2.5mg Oral Tablet (US$), February’2021

Figure 5-32: Glucotrol XL – Cost of Supply of 100 and 500 Tablets of 5mg Oral Tablet (US$), February’2021

Figure 5-33: Glucotrol XL – Cost of Supply of 100 and 500 Tablets of 10mg Oral Tablet (US$), February’2021

Figure 5-34: Glipizide – Cost of Supply of 30, 90 and 100 Oral Tablets (5mg) (US$), February’2021

Figure 5-35: Glipizide – Cost of Supply of 30, 90 and 100 Oral Tablets (10mg) (US$), February’2021

Figure 5-36: Glipizide – Cost of Supply of 30 Tablets and Per Unit Price of 2.5mg Oral ER Tablet (US$), February’2021

Figure 5-37: Glipizide – Cost of Supply of 100, 500 and 1000 of 5mg Oral ER Tablet (US$), February’2021

Figure 5-38: Glipizide – Cost of Supply of 100, 500 and 1000 of 10mg Oral ER Tablet (US$), February’2021

Figure 5-39: Glipizide – Maximum Recommended Dose by Oral Tablet (mg/day)

Figure 5-40: Tolzamide – Cost of Supply of 90 Tablets and Per Unit Cost of 250mg Tablet (US$), February’2021

Figure 5-41: Tolzamide – Cost of Supply of 100 Tablets and Per Unit Cost of 250mg Tablet (US$), February’2021

Figure 5-42: Tolzamide – Cost of Supply of 100 Tablets and Per Unit Cost of 500mg Tablet (US$), February’2021

Figure 5-43: Tolzamide – Maximum and Minimum Recommended Dose (mg)

Figure 5-44: Tolbutamide – Cost of Supply of 100 Tablets and Per Unit Cost of 500mg Tablet (US$), February’2021

Figure 5-45: Tolbutamide – Maximum and Minimum Recommended Dose (mg)

Figure 6-1: Pioglitazone – FDA Approval and Patent Expiration Year

Figure 6-2: Pioglitazone – FDA Approval and 1st Generic Approval Year

Figure 6-3: Actos – Cost of Supply of 30, 90 and 500 Tablets of 15mg Oral Tablet (US$), February’2021

Figure 6-4: Actos – Cost of Supply of 30 and 500 Tablets of 30mg Oral Tablet (US$), February’2021

Figure 6-5: Actos – Cost of Supply of 30 and 500 Tablets of 45mg Oral Tablet (US$), February’2021

Figure 6-6: Pioglitazone – Cost of Supply of 30, 90 and 500 Tablets of 15mg Oral Tablet (US$), February’2021

Figure 6-7: Pioglitazone – Cost of Supply of 30, 90 and 500 Tablets of 30mg Oral Tablet (US$), February’2021

Figure 6-8: Pioglitazone – Cost of Supply of 30, 90 and 500 Tablets of 45mg Oral Tablet (US$), February’2021

Figure 6-9: Pioglitazone – Maximum and Minimum Recommended Dose (mg)

Figure 6-10: Pioglitazone – Maximum and Minimum Cost of Treatment per Day with Branded and Generic Drugs

Figure 6-11: US - Rosiglitazone Patent Approval and Expiration Year

Figure 6-12: Rosiglitazone – Cost of Supply of 60 Tablets and Per Unit Cost of 2mg Oral Tablet (US$), February’2021

Figure 6-13: Rosiglitazone – Cost of Supply of 30 Tablets and Per Unit Cost of 4mg Oral Tablet (US$), February’2021

Figure 6-14: Rosiglitazone – Maximum and Minimum Recommended Dose (mg)

Figure 7-1: Liraglutide – FDA Approval and Patent Expiration Year

Figure 7-2: Victoza – Cost of Supply of 6ml and Per Unit Cost of Subcutaneous Soltuion (US$), February’2021

Figure 7-3: Victoza – Cost of Supply of 9ml and Per Unit Cost of Subcutaneous Soltuion (US$), February’2021

Figure 7-4: Victoza – Maximum and Minimum Recommended Dose (mg)

Figure 7-5: Global – Victoza Annual Sales (US$ Million), 2018-2020

Figure 7-6: US - Victoza Annual Sales (US$ Million), 2018-2020

Figure 7-7: Victoza – Annual Sales by Region (%), 2019

Figure 7-8: Victoza – Annual Sales by Region (%), 2020

Figure 7-9: US – Exenatide FDA Approval and Patent Expiration Year

Figure 7-10: US – Exenatide FDA Approval by Brand

Figure 7-11: Byetta – Cost of Supply of 1.2ml and Per Unit Cost of 5mcg/0.02ml Subcutaneous Soltuion (US$), February’2021

Figure 7-12: Byetta – Cost of Supply of 2.4ml and Per Unit Cost of 10mcg/0.04ml Subcutaneous Soltuion (US$), February’2021

Figure 7-13: Bydureon – Cost of Supply of 4 and Per Unit Cost of 2mg Subcutaneous Powder (US$), February’2021

Figure 7-14: Bydureon BCise – Cost of Supply of 3.4ml and Per Unit Cost of Subcutaneous Suspension (US$), February’2021

Figure 7-15: Global – Bydureon Annual Sales (US$ Million), 2017-2019

Figure 7-16: US - Bydureon Annual Sales (US$ Million), 2017-2019

Figure 7-17: Bydureon – Annual Sales by Region (%), 2019

Figure 7-18: Global – Bydureon Quarterly Sales (US$ Million), 2020

Figure 7-19: US - Bydureon Quarterly Sales (US$ Million), 2020

Figure 7-20: Bydureon – Annual Sales by Region (%), 2020

Figure 7-21: Global – Byetta Annual Sales (US$ Million), 2017-2019

Figure 7-22: US - Byetta Annual Sales (US$ Million), 2017-2019

Figure 7-23: Byetta – Annual Sales by Region (%), 2019

Figure 7-24: Global – Byetta Quarterly Sales (US$ Million), 2020

Figure 7-25: US - Byetta Quarterly Sales (US$ Million), 2020

Figure 7-26: Byetta – Annual Sales by Region (%), 2020

Figure 7-27: Semaglutide – FDA Approval and Patent Expiration Year

Figure 7-28: Semaglutide – FDA Approval by Brand

Figure 7-29: Ozempic – Cost of Supply of 1.5ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 7-30: Ozempic – Cost of Supply of 3ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 7-31: Ozempic – Maximum and Minimum Recommended Dose (mg)

Figure 7-32: Rybelsus – Cost of Supply of 30 Tablets and Per Unit Price of Oral Tablet (US$), February’2021

Figure 7-33: Rybelsus – Maximum and Minimum Recommended Dose (mg)

Figure 7-34: Global – Ozempic Annual Sales (US$ Million), 2018-2020

Figure 7-35: US - Ozempic Annual Sales (US$ Million), 2018-2020

Figure 7-36: Ozempic – Annual Sales by Region (%), 2019

Figure 7-37: Ozempic – Annual Sales by Region (%), 2020

Figure 7-38: Global – Rybelsus Annual Sales (US$ Million), 2019 and 2020

Figure 7-39: US - Rybelsus Annual Sales (US$ Million), 2019 and 2020

Figure 7-40: Rybelsus – Annual Sales by Region (%), 2020

Figure 7-41: US - Dulaglutide FDA Approval and Patent Exclusivity Year

Figure 7-42: Trulicity – Cost of Supply of 2ml and Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 7-43: Trulicity – Maximum and Minimum Recommended Dose (mg)

Figure 7-44: Global – Trulicity Annual Sales (US$ Million), 2017-2020

Figure 7-45: US - Lixisenatide FDA Approval and Patent Expiration Year

Figure 7-46: Adlyxin – Cost of Supply 6ml and Per Unit Price of Subcutaneous Kit/Solution (US$), February’2021

Figure 7-47: Adlyxin – Recommended Initial Dose and Maintenance Dose (mcg)

Figure 8-1: US - Sitagliptin FDA Approval and Patent Exclusivity Year

Figure 8-2: Januvia – Cost of Supply of 30, 90 and 100 Oral Tablets (US$), February’2021

Figure 8-3: Januvia –Recommended Initial Dose and Subsequent Reductions (mg)

Figure 8-4: Global – Januvia Annual Sales (US$ Million), 2017-2019

Figure 8-5: US - Januvia Annual Sales (US$ Million), 2017-2019

Figure 8-6: Januvia – Annual Sales by Region (%), 2019

Figure 8-7: Global - Januvia Quarterely Sales (US$ Million), 2020

Figure 8-8: US - Saxagliptin FDA Approval and Patent Expiration Year

Figure 8-9: Onglyza – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-10: Onglyza – Cost of Supply of 90 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-11: Onglyza – Cost of Daily, Monthly and Annual Treatment (US$)

Figure 8-12: Global – Onglyza Annual Sales (US$ Million), 2017-2019

Figure 8-13: US - Onglyza Annual Sales (US$ Million), 2017-2019

Figure 8-14: Onglyza – Annual Sales by Region (%), 2019

Figure 8-15: Global – Onglyza Quarterly Sales (US$ Million), 2020

Figure 8-16: US - Onglyza Quarterly Sales (US$ Million), 2020

Figure 8-17: Onglyza – Annual Sales by Region (%), 2020

Figure 8-18: US - Linagliptin FDA Approval and Patent Expiration Year

Figure 8-19: Tradjenta – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-20: Tradjenta – Cost of Supply of 90 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-21: Tradjenta – Cost of Supply of 100 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-22: Tradjenta – Cost of Daily, Monthly and Annual Treatment (US$)

Figure 8-23: US – Alogliptin Patent Approval and Expiration Year

Figure 8-24: US - Alogliptin FDA Approval and Patent Expiration Year

Figure 8-25: Nesina – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 8-26: Nesina –Recommended Initial Dose and Subsequent Reductions (mg)

Figure 9-1: US – Canagliflozin Patent Approval and Expiration Year

Figure 9-2: Invokana – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-3: Invokana – Cost of Supply of 90 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-4: Invokana – Maximum and Minimum Recommended Dose (mg)

Figure 9-5: Global – Invokana Annual Sales (US$ Million), 2017-2019

Figure 9-6: US - Invokana Annual Sales (US$ Million), 2017-2019

Figure 9-7: Invokana – Annual Sales by Region (%), 2019

Figure 9-8: Global – Invokana Quarterly Sales (US$ Million), 2019 and 2020

Figure 9-9: US - Invokana Quarterly Sales (US$ Million), 2019 and 2020

Figure 9-10: Invokana – Annual Sales by Region (%), 2020

Figure 9-11: US - Ertugliflozin FDA Approval and Patent Exclusivity Year

Figure 9-12: US – Ertugliflozin Patent Approval and Expiration Year

Figure 9-13: Steglatro – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-14: Steglatro – Cost of Supply of 90 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-15: Steglatro – Cost of Supply of 500 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-16: Steglatro – Maximum and Minimum Recommended Dose (mg)

Figure 9-17: US – Ertugliflozin Patent Approval and Expiration Year

Figure 9-18: Jardiance – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-19: Jardiance – Cost of Supply of 90 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-20: Jardiance – Maximum and Minimum Recommended Dose (mg)

Figure 9-21: Global – Jardiance Annual Sales (US$ Million), 2017-2020

Figure 9-22: US - Linagliptin FDA Approval and Patent Expiration Year

Figure 9-23: US – Dapagliflozin Patent Approval and Expiration Year

Figure 9-24: Farxiga – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-25: Farxiga – Maximum and Minimum Recommended Dose (mg)

Figure 9-26: Global – Farxiga Annual Sales (US$ Million), 2017-2019

Figure 9-27: US - Farxiga Annual Sales (US$ Million), 2017-2019

Figure 9-28: Farxiga – Annual Sales by Region (%), 2019

Figure 9-29: Global – Farxiga Quarterly Sales (US$ Million), 2020

Figure 9-30: US - Farxiga Quarterly Sales (US$ Million), 2020

Figure 9-31: Farxiga – Annual Sales by Region (%), 2020

Figure 10-1: Repaglinide – Cost of Supply of 100 and Per Unit Price of Oral Tablet of 0.5mg (US$), February’2021

Figure 10-2: Repaglinide – Cost of Supply of 30, 100 and 500 Oral Tablets of 1mg (US$), February’2021

Figure 10-3: Repaglinide – Cost of Supply of 100 and 500 Oral Tablets of 2mg (US$), February’2021

Figure 10-4: Repaglinide – Maximum and Minimum Recommended Dose (mg)

Figure 10-5: Nateglinide – Cost of Supply of 30, 90 and 100 Oral Tablets of 60mg (US$), February’2021

Figure 10-6: Nateglinide – Cost of Supply of 30, 90 and 100 Oral Tablets of 120mg (US$), February’2021

Figure 11-1: US – Miglitol FDA Approval and Generic Availability Year

Figure 11-2: Glyset – Cost of Supply of 100 and Per Unit Price of 25mg Oral Tablet (US$), February’2021

Figure 11-3: Glyset – Cost of Supply of 100 and Per Unit Price of 50mg Oral Tablet (US$), February’2021

Figure 11-4: Glyset – Cost of Supply of 100 and Per Unit Price of 100mg Oral Tablet (US$), February’2021

Figure 11-5: Miglitol – Cost of Supply of 100 and Per Unit Price of 25mg Oral Tablet (US$), February’2021

Figure 11-6: Miglitol – Cost of Supply of 100 and Per Unit Price of 50mg Oral Tablet (US$), February’2021

Figure 11-7: Miglitol – Cost of Supply of 100 and Per Unit Price of 100mg Oral Tablet (US$), February’2021

Figure 11-8: Miglitol – Maximum and Minimum Recommended Dose (mg)

Figure 11-9: Acarbose – Cost of Supply of 90, 100 and 1000 Oral Tablets of 25mg (US$), February’2021

Figure 11-10: Acarbose – Cost of Supply of 90, 100 and 1000 Oral Tablets of 50mg (US$), February’2021

Figure 11-11: Acarbose – Cost of Supply of 90, 100 and 1000 Oral Tablets of 100mg (US$), February’2021

Figure 11-12: Acarbose – Maximum Recommended Dose by Weight (mg)

Figure 12-1: US – Metformin/Sitagliptin FDA Approval by Brand

Figure 12-2: US – Janumet Patent Approval and Expiration Year

Figure 12-3: US – Janumet XR Patent Approval and Expiration Year

Figure 12-4: Janumet – Cost of Supply of 60, 180 and 1000 Oral Tablets (US$), February’2021

Figure 12-5: Janumet XR – Cost of Supply of 60, 180 and 1000 Oral Tablets (US$), February’2021

Figure 12-6: Global – Janumet Annual Sales (US$ Million), 2017-2019

Figure 12-7: US - Janumet Annual Sales (US$ Million), 2017-2019

Figure 12-8: Janumet – Annual Sales by Region (%), 2019

Figure 12-9: Global - Janumet Quarterely Sales (US$ Million), 2020

Figure 12-10: US – Duetact FDA Approval and Generic ApprovalYear

Figure 12-11: US – Duetact Patent Approval and Expiration Year

Figure 12-12: Duetact – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-13: Glimepiride/Pioglitazone – Cost of Supply of 30 and Per Unit Price of 2mg-30mg Oral Tablet (US$), February’2021

Figure 12-14: Glimepiride/Pioglitazone – Cost of Supply of 30 and Per Unit Price of 4mg-30mg Oral Tablet (US$), February’2021

Figure 12-15: US – Glyburide/Metformin FDA Approval and Generic Availability Year

Figure 12-16: Glucovance – Cost of Supply of 100 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-17: Glyburide/Metformin – Cost of Supply of 100 and 500 Oral Tablets of 1.25mg (US$), February’2021

Figure 12-18: Glyburide/Metformin – Cost of Supply of 100 and 500 Oral Tablets of 2.5mg (US$), February’2021

Figure 12-19: Glyburide/Metformin – Cost of Supply of 100 and 500 Oral Tablets of 2.5mg (US$), February’2021

Figure 12-20: Glyburide/Metformin – Maximum and Minimum Recommended Dose (mg)

Figure 12-21: US – Dapagliflozin/Metformin Patent Approval and Expiration Year

Figure 12-22: Xigduo – Cost of Supply of 30 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-23: US – Synjardy Patent Approval and Expiration Year

Figure 12-24: US – Synjardy XR Patent Approval and Expiration Year

Figure 12-25: Synjardy – Cost of Supply of 60 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-26: Synjardy – Cost of Supply of 180 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-27: Glipizide/Metformin – Cost of Supply of 100 and Per Unit Price of 2.5mg-250mg Oral Tablet (US$), February’2021

Figure 12-28: Glipizide/Metformin – Cost of Supply of 100 and Per Unit Price of 2.5mg-500mg Oral Tablet (US$), February’2021

Figure 12-29: Glipizide/Metformin – Cost of Supply of 100 and Per Unit Price of 5mg-500mg Oral Tablet (US$), February’2021

Figure 12-30: US – Linagliptin/Metformin FDA Approval by Brand

Figure 12-31: US – Jantadueto Patent Approval and Expiration Year

Figure 12-32: Jantadeuto – Cost of Supply of 60 and Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-33: Jantadeuto – Cost of Supply of 180 and Per Unit Price of Oral Tablet (US$), February’2021

Fi